Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2019 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
February 27, 2019 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

-- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI -- -- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA -- --...
February 14, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
February 13, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019

BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
February 06, 2019 17:05 ET | Source: Paratek Pharmaceuticals

New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections

BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
February 05, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States

-- Three Antimicrobial Susceptibility Tests Cleared by FDA for Use with NUZYRA -- -- Launches KEYSTONETM Surveillance Program to Monitor Omadacycline Susceptibility -- BOSTON, Feb. 05, 2019 ...
February 01, 2019 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today...
January 02, 2019 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today...
December 03, 2018 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030

BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
November 27, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections

BOSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...